Evan Doran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Evan Doran has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- David Henry
Affiliations School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia, Institute for Evidence Based Healthcare, Bond University, Gold Coast, Queensland, Australia
18 shared publications - Ian Kerridge
The University of Sydney, Sydney, Australia
9 shared publications - Andrew Searles
Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia
3 shared publications - David Newby
School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia
3 shared publications - Richard Osborne Day
St Vincent’s Clinical Campus, School of Medicine, St Vincent’s Hospital, University of New South Wales, Darlinghurst, Australia
3 shared publications B. J. Stokes
Discipline of Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia, and
2 shared publications
Latest Publications
- Open Access
- 21 February 2016
- Published by Maad Rayan Publishing Company in International Journal of Health Policy and Management
- Vol. 5 (5) , 333-335
Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: Teaching Drug Marketers How to Inform Better or Spin Better? Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters"
Hyosun Kim’s report “Trouble Spots in Online Direct to Consumer Prescription Drug Promotion: A content Analysis of FDA Warning Letters”aims to teach marketers how to avoid breaching current Food and Drug Administration (FDA) guidelines in their online drug promotion. While Kim hopes to minimise the potential for online promotion to misinform consumers and the study is carefully conducted, teaching drug marketers how to avoid the common mistakes in online drug promotion is more likely to make marketers more adept at spinning information than appropriately balancing it.
- 21 February 2016
- Published by Maad Rayan Publishing Company in International Journal of Health Policy and Management
- Vol. 5 (5) , 333-335
Open AccessTrouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: Teaching Drug Marketers How to Inform Better or Spin Better? Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters"
Hyosun Kim’s report “Trouble Spots in Online Direct to Consumer Prescription Drug Promotion: A content Analysis of FDA Warning Letters”aims to teach marketers how to avoid breaching current Food and Drug Administration (FDA) guidelines in their online drug promotion. While Kim hopes to minimise the potential for online promotion to misinform consumers and the study is carefully conducted, teaching drug marketers how to avoid the common mistakes in online drug promotion is more likely to make marketers more adept at spinning information than appropriately balancing it.
- 20 November 2015
- Published by Wiley in Journal of Advanced Nursing
- Vol. 72 (3) , 488-500
Mixed method integrative review exploring nurses’ recognition and response to unsafe practice
Aim: To determine how nurses recognize and respond to unsafe practice.Background: Practice guidelines and standards outline safe practice. Nurses face challenges in recognizing and responding unsafe practice.Design: Whittemore and Knafl's revised framework for integrative reviews guided the analysis.Data sources: A comprehensive search of literature exploring the identification and response to unsafe practice, was undertaken in CINAHL, Medline, Embase and PsychoINFO databases for the period 2004–2014.Review methods: Nineteen articles from 15 studies were included in the review. A mixed method integrative approach was used to review data and draw conclusions.Results: Behaviours and cues that indicate unsafe practice are influenced by organizational and individual characteristics. Individual nurses responses are variable and there are professional and personal costs associated with being reported or reporting unsafe practice.Conclusion: The small number of studies reviewed limits the conclusions that can be drawn from the review but suggest that nurses can identify unsafe practice in their peers. Individual nurses’ recognition and response to unsafe practice in their peers contributes to patient outcomes and safety. Nurses need awareness training and strategies to respond to unsafe practice and reporting systems that protect reporters from repercussions. Further research investigating organizational factors and individual factors that contribute to a shift in practice across safety boundaries is required.
- 20 November 2015
- Published by Wiley in Journal of Advanced Nursing
- Vol. 72 (3) , 488-500
Mixed method integrative review exploring nurses’ recognition and response to unsafe practice
Aim: To determine how nurses recognize and respond to unsafe practice.Background: Practice guidelines and standards outline safe practice. Nurses face challenges in recognizing and responding unsafe practice.Design: Whittemore and Knafl's revised framework for integrative reviews guided the analysis.Data sources: A comprehensive search of literature exploring the identification and response to unsafe practice, was undertaken in CINAHL, Medline, Embase and PsychoINFO databases for the period 2004–2014.Review methods: Nineteen articles from 15 studies were included in the review. A mixed method integrative approach was used to review data and draw conclusions.Results: Behaviours and cues that indicate unsafe practice are influenced by organizational and individual characteristics. Individual nurses responses are variable and there are professional and personal costs associated with being reported or reporting unsafe practice.Conclusion: The small number of studies reviewed limits the conclusions that can be drawn from the review but suggest that nurses can identify unsafe practice in their peers. Individual nurses’ recognition and response to unsafe practice in their peers contributes to patient outcomes and safety. Nurses need awareness training and strategies to respond to unsafe practice and reporting systems that protect reporters from repercussions. Further research investigating organizational factors and individual factors that contribute to a shift in practice across safety boundaries is required.
- 15 June 2015
- Published by Wiley in Medical Journal of Australia
- Vol. 202 (11) , 587-590
Part of the fabric and mostly right: an ethnography of ethics in clinical practice
Would clinical ethics support services be useful in Australian hospitals?
- 15 June 2015
- Published by Wiley in Medical Journal of Australia
- Vol. 202 (11) , 587-590
Part of the fabric and mostly right: an ethnography of ethics in clinical practice
Would clinical ethics support services be useful in Australian hospitals?
- Open Access
- 17 December 2014
- Published by CSIRO Publishing in Australian Health Review
- Vol. 39 (1) , 44-50
Managing ethical issues in patient care and the need for clinical ethics support
Objective: To investigate the range, frequency and management of ethical issues encountered by clinicians working in hospitals in New South Wales (NSW), Australia. Methods: A cross-sectional survey was conducted of a convenience sample of 104 medical, nursing and allied health professionals in two NSW hospitals. Results: Some respondents did not provide data for some questions, therefore the denominator is less than 105 for some items. Sixty-two (62/104; 60%) respondents reported occasionally to often having ethical concerns. Forty-six (46/105; 44%) reported often to occasionally having legal concerns. The three most common responses to concerns were: talking to colleagues (96/105; 91%); raising the issue in a group forum (68/105; 65%); and consulting a relevant guideline (64/105; 61%). Most respondents were highly (65/99; 66%) or moderately (33/99; 33%) satisfied with the ethical environment of the hospital. Twenty-two (22/98; 22%) were highly satisfied with the ethical environment of their department and 74 (74/98; 76%) were moderately satisfied. Most (72/105; 69%) respondents indicated that additional support in dealing with ethical issues would be helpful. Conclusion: Clinicians reported frequently experiencing ethical and legal uncertainty and concern. They usually managed this by talking with colleagues. Although this approach was considered adequate, and the ethics of their hospital was reported to be satisfactory, most respondents indicated that additional assistance with ethical and legal concerns would be helpful. Clinical ethics support should be a priority of public hospitals in NSW and elsewhere in Australia. What is known about the topic?: Clinicians working in hospitals in the US, Canada and UK have access to ethics expertise to help them manage ethical issues that arise in patient care. How Australian clinicians currently manage the ethical issues they face has not been investigated. What does this paper add?: This paper describes the types of ethical issues faced by Australian clinicians, how they manage these issues and whether they think ethics support would be helpful. What are the implications for practitioners?: Clinicians frequently encounter ethically and legally difficult decisions and want additional ethics support. Helping clinicians to provide ethically sound patient care should be a priority of public hospitals in NSW and elsewhere in Australia.
- 17 December 2014
- Published by CSIRO Publishing in Australian Health Review
- Vol. 39 (1) , 44-50
Open AccessManaging ethical issues in patient care and the need for clinical ethics support
Objective: To investigate the range, frequency and management of ethical issues encountered by clinicians working in hospitals in New South Wales (NSW), Australia. Methods: A cross-sectional survey was conducted of a convenience sample of 104 medical, nursing and allied health professionals in two NSW hospitals. Results: Some respondents did not provide data for some questions, therefore the denominator is less than 105 for some items. Sixty-two (62/104; 60%) respondents reported occasionally to often having ethical concerns. Forty-six (46/105; 44%) reported often to occasionally having legal concerns. The three most common responses to concerns were: talking to colleagues (96/105; 91%); raising the issue in a group forum (68/105; 65%); and consulting a relevant guideline (64/105; 61%). Most respondents were highly (65/99; 66%) or moderately (33/99; 33%) satisfied with the ethical environment of the hospital. Twenty-two (22/98; 22%) were highly satisfied with the ethical environment of their department and 74 (74/98; 76%) were moderately satisfied. Most (72/105; 69%) respondents indicated that additional support in dealing with ethical issues would be helpful. Conclusion: Clinicians reported frequently experiencing ethical and legal uncertainty and concern. They usually managed this by talking with colleagues. Although this approach was considered adequate, and the ethics of their hospital was reported to be satisfactory, most respondents indicated that additional assistance with ethical and legal concerns would be helpful. Clinical ethics support should be a priority of public hospitals in NSW and elsewhere in Australia. What is known about the topic?: Clinicians working in hospitals in the US, Canada and UK have access to ethics expertise to help them manage ethical issues that arise in patient care. How Australian clinicians currently manage the ethical issues they face has not been investigated. What does this paper add?: This paper describes the types of ethical issues faced by Australian clinicians, how they manage these issues and whether they think ethics support would be helpful. What are the implications for practitioners?: Clinicians frequently encounter ethically and legally difficult decisions and want additional ethics support. Helping clinicians to provide ethically sound patient care should be a priority of public hospitals in NSW and elsewhere in Australia.
- Open Access
- 13 October 2014
- Published by Nova Southeastern University in The Qualitative Report
- Vol. 19, 1-18
Potency, Hubris and Susceptibility: The Disease Mongering Critique of Pharmaceutical Marketing
The phrase “disease mongering” has become a prominent feature of the wider critique of pharmaceutical marketing. Disease mongering refers to drug companies’ involvement in informing the lay public and health professionals about the illnesses targeted by their products. Typically, drug promotion is claimed to intentionally distort perceptions of the seriousness or treatability of disease or condition to sell drugs. The main concern is that drug promotion results in excessive drug demand. “Disease mongering” is clearly aimed at drug companies, however, the phrase reaches further and extends to us all with its often implicit critical commentary on contemporary social life. In this report, describe the results of an interview study with critics of pharmaceutical marketing. We explore what disease mongering implies or assumes about the contemporary world, particularly the doctors and consumers who inhabit it, and why such a critique is considered necessary. The potency of the drug promotion, the hubris of doctors the susceptibility of consumers were the main themes interpreted in the data. The disease mongering critique can be seen as part of a more general critique of the processes of “biomedicalisation” and “pharmaceuticalisation.”
- 13 October 2014
- Published by Nova Southeastern University in The Qualitative Report
- Vol. 19, 1-18
Open AccessPotency, Hubris and Susceptibility: The Disease Mongering Critique of Pharmaceutical Marketing
The phrase “disease mongering” has become a prominent feature of the wider critique of pharmaceutical marketing. Disease mongering refers to drug companies’ involvement in informing the lay public and health professionals about the illnesses targeted by their products. Typically, drug promotion is claimed to intentionally distort perceptions of the seriousness or treatability of disease or condition to sell drugs. The main concern is that drug promotion results in excessive drug demand. “Disease mongering” is clearly aimed at drug companies, however, the phrase reaches further and extends to us all with its often implicit critical commentary on contemporary social life. In this report, describe the results of an interview study with critics of pharmaceutical marketing. We explore what disease mongering implies or assumes about the contemporary world, particularly the doctors and consumers who inhabit it, and why such a critique is considered necessary. The potency of the drug promotion, the hubris of doctors the susceptibility of consumers were the main themes interpreted in the data. The disease mongering critique can be seen as part of a more general critique of the processes of “biomedicalisation” and “pharmaceuticalisation.”
- 8 September 2014
- Published by Wiley in Internal Medicine Journal
- Vol. 44 (9) , 841-845
Dilemmas in the compassionate supply of investigational cancer drugs
In Australia, patients who want to access medicines that are not yet approved have only two options: to enrol in a clinical trial if they are eligible, or obtain their medicine through ‘compassionate supply’, which is provided at the discretion of the manufacturer. In this article, we explore ethical issues associated with the provision of oncology medicines that are still in development, either prior to regulatory approval or government reimbursement.
- 8 September 2014
- Published by Wiley in Internal Medicine Journal
- Vol. 44 (9) , 841-845
Dilemmas in the compassionate supply of investigational cancer drugs
In Australia, patients who want to access medicines that are not yet approved have only two options: to enrol in a clinical trial if they are eligible, or obtain their medicine through ‘compassionate supply’, which is provided at the discretion of the manufacturer. In this article, we explore ethical issues associated with the provision of oncology medicines that are still in development, either prior to regulatory approval or government reimbursement.
- 4 March 2014
- Published by CSIRO Publishing in Australian Health Review
- Vol. 38 (2) , 160-168
Challenges to pharmaceutical policymaking: lessons from Australia’s national medicines policy
Objective: National medicines policies (NMP) provide a means for governments to achieve their objectives in relation to pharmaceuticals and other medicines. This research aimed to identify challenges to implementing the objectives of the Australian NMP from the perspective of key stakeholders. Methods: In 2012 and 2103, we conducted 30 semistructured interviews with stakeholders involved in the discovery, clinical testing, regulation and funding of medicines in Australia. We asked participants to describe their careers and to give their opinions on specific issues surrounding drug development, clinical research, regulation and subsidisation in Australia. Data were analysed using Morse’s outline of the cognitive basis of qualitative research and Charmaz’s outline of data analysis in grounded theory. The initial phase of ‘open coding’ revealed findings that could be mapped to three of the four objectives of the NMP. We then conducted ‘focussed coding’ for themes relevant to these objectives. Results: Participants identified many issues relevant to the ongoing evolution of the NMP, relating primarily to ongoing tensions between the commercial objective of ensuring a viable medicines industry, and the non-commercial objectives of ensuring that medicines are safe, effective and affordable. There were also several other challenges identified to the achievement of both the commercial and non-commercial objectives of the NMP. These included limits to government funding, globalisation, consumer advocacy, changing scientific paradigms and new information technologies. Conclusions: There are many issues that need to be addressed if policymakers are to achieve the best outcomes from the NMP. Tensions between the commercial and non-commercial objectives of the NMP suggest the need to ensure that one stakeholder group’s imperatives do not stifle those of other groups. At the same time, there are several emerging issues that are likely to concern all stakeholders equally, and these are both challenges and opportunities for new kinds of collaboration. What is known about the topic?: We know that stakeholders have several concerns about medicines policy, but little is known about the specific challenges to implementing medicines policy from the perspective of those involved. What does this paper add?: We demonstrate that stakeholders have many concerns that could impact the implementation of medicines policies. These relate primarily to ongoing tensions between the objective of ensuring a viable medicines industry, and the objectives of ensuring that medicines are safe, effective and affordable. There are also several issues that potentially pose a challenge to achieving both the commercial and non-commercial objectives of the NMP. These include limits to government funding, globalisation, consumer advocacy, changing scientific paradigms and new information technologies. What are the implications for practitioners?: Policymakers need to systematically address the barriers to the ongoing implementation of the NMP. Policymakers should also ensure that one imperative (such as the commercial imperative) does not stifle other objectives. Other emerging issues are likely to concern all stakeholders, and these provide opportunities for new kinds of collaboration among stakeholders.
- 4 March 2014
- Published by CSIRO Publishing in Australian Health Review
- Vol. 38 (2) , 160-168
Challenges to pharmaceutical policymaking: lessons from Australia’s national medicines policy
Objective: National medicines policies (NMP) provide a means for governments to achieve their objectives in relation to pharmaceuticals and other medicines. This research aimed to identify challenges to implementing the objectives of the Australian NMP from the perspective of key stakeholders. Methods: In 2012 and 2103, we conducted 30 semistructured interviews with stakeholders involved in the discovery, clinical testing, regulation and funding of medicines in Australia. We asked participants to describe their careers and to give their opinions on specific issues surrounding drug development, clinical research, regulation and subsidisation in Australia. Data were analysed using Morse’s outline of the cognitive basis of qualitative research and Charmaz’s outline of data analysis in grounded theory. The initial phase of ‘open coding’ revealed findings that could be mapped to three of the four objectives of the NMP. We then conducted ‘focussed coding’ for themes relevant to these objectives. Results: Participants identified many issues relevant to the ongoing evolution of the NMP, relating primarily to ongoing tensions between the commercial objective of ensuring a viable medicines industry, and the non-commercial objectives of ensuring that medicines are safe, effective and affordable. There were also several other challenges identified to the achievement of both the commercial and non-commercial objectives of the NMP. These included limits to government funding, globalisation, consumer advocacy, changing scientific paradigms and new information technologies. Conclusions: There are many issues that need to be addressed if policymakers are to achieve the best outcomes from the NMP. Tensions between the commercial and non-commercial objectives of the NMP suggest the need to ensure that one stakeholder group’s imperatives do not stifle those of other groups. At the same time, there are several emerging issues that are likely to concern all stakeholders equally, and these are both challenges and opportunities for new kinds of collaboration. What is known about the topic?: We know that stakeholders have several concerns about medicines policy, but little is known about the specific challenges to implementing medicines policy from the perspective of those involved. What does this paper add?: We demonstrate that stakeholders have many concerns that could impact the implementation of medicines policies. These relate primarily to ongoing tensions between the objective of ensuring a viable medicines industry, and the objectives of ensuring that medicines are safe, effective and affordable. There are also several issues that potentially pose a challenge to achieving both the commercial and non-commercial objectives of the NMP. These include limits to government funding, globalisation, consumer advocacy, changing scientific paradigms and new information technologies. What are the implications for practitioners?: Policymakers need to systematically address the barriers to the ongoing implementation of the NMP. Policymakers should also ensure that one imperative (such as the commercial imperative) does not stifle other objectives. Other emerging issues are likely to concern all stakeholders, and these provide opportunities for new kinds of collaboration among stakeholders.
- Open Access
- 14 December 2012
- Published by CSIRO Publishing in Australian Health Review
- Vol. 37 (1) , 32-40
The affordability of prescription medicines in Australia: are copayments and safety net thresholds too high?
Objective.: To create and report survey-based indicators of the affordability of prescription medicines for patients in Australia. Method.: A cross-sectional study of 1502 randomly selected participants in the Hunter Region of NSW, were interviewed by telephone. Main outcome measure.: The self-reported financial burden of obtaining prescription medicines. Results.: Data collection was completed with a response rate of 59.0%. Participants who had received and filled at least one prescription medicine in the previous 3 months, and eligible for analysis (n=952), were asked to self-report the level of financial burden from obtaining these medicines. Extreme and heavy financial burdens were reported by 2.1% and 6.8% of participants, respectively. A moderate level of burden was experienced by a further 19.5%. Low burden was recorded for participants who said that their prescription medicines presented either a slight burden (29.0%) or were no burden at all (42.6%). Conclusion.: A substantial minority of participants who had obtained prescription medicines in the 3 months prior to survey experienced a level of financial burden from the cost of these medicines that was reported as being moderate to extreme. What is known about the topic?: The Australian National Medicines Policy aims to, amongst other things, facilitate access to medicines at a cost that is affordable to individuals and the community. Copayments combined with the safety net and brand price premium are the main determinants of the amount that patients pay for PBS listed prescription medicines. Previous surveys have reported on selected aspects of medicine affordability in Australia and have shown some groups in the population experience difficulty with the cost of their medicines. What does this paper add?: This paper develops and reports on a set of indicators that can be used to periodically measure the level of self-reported financial burden experienced by Australians when obtaining prescription medicines. The analysis assesses affordability issues for both general patients and patients who are able to access prescription medicines using a concession card. What are the implications?: Our research suggests that, as they stand, the copayment and safety net thresholds are not protecting nearly one-third of Australian patients from financial burden. Ongoing monitoring and evaluation is required to ensure the copayment and safety net thresholds do not jeopardise the National Medicines Policy’s principle of equitable and affordable access to medicines.
- 14 December 2012
- Published by CSIRO Publishing in Australian Health Review
- Vol. 37 (1) , 32-40
Open AccessThe affordability of prescription medicines in Australia: are copayments and safety net thresholds too high?
Objective.: To create and report survey-based indicators of the affordability of prescription medicines for patients in Australia. Method.: A cross-sectional study of 1502 randomly selected participants in the Hunter Region of NSW, were interviewed by telephone. Main outcome measure.: The self-reported financial burden of obtaining prescription medicines. Results.: Data collection was completed with a response rate of 59.0%. Participants who had received and filled at least one prescription medicine in the previous 3 months, and eligible for analysis (n=952), were asked to self-report the level of financial burden from obtaining these medicines. Extreme and heavy financial burdens were reported by 2.1% and 6.8% of participants, respectively. A moderate level of burden was experienced by a further 19.5%. Low burden was recorded for participants who said that their prescription medicines presented either a slight burden (29.0%) or were no burden at all (42.6%). Conclusion.: A substantial minority of participants who had obtained prescription medicines in the 3 months prior to survey experienced a level of financial burden from the cost of these medicines that was reported as being moderate to extreme. What is known about the topic?: The Australian National Medicines Policy aims to, amongst other things, facilitate access to medicines at a cost that is affordable to individuals and the community. Copayments combined with the safety net and brand price premium are the main determinants of the amount that patients pay for PBS listed prescription medicines. Previous surveys have reported on selected aspects of medicine affordability in Australia and have shown some groups in the population experience difficulty with the cost of their medicines. What does this paper add?: This paper develops and reports on a set of indicators that can be used to periodically measure the level of self-reported financial burden experienced by Australians when obtaining prescription medicines. The analysis assesses affordability issues for both general patients and patients who are able to access prescription medicines using a concession card. What are the implications?: Our research suggests that, as they stand, the copayment and safety net thresholds are not protecting nearly one-third of Australian patients from financial burden. Ongoing monitoring and evaluation is required to ensure the copayment and safety net thresholds do not jeopardise the National Medicines Policy’s principle of equitable and affordable access to medicines.
- Open Access
- 3 April 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (4) , e34314
A Prompt to the Web: The Media and Health Information Seeking Behaviour
The objective was to investigate media influence on consumers' health related behaviours. A cross-sectional survey of randomly selected adults (18+ years) residing in the Hunter Region of New South Wales Australia was conducted. The sample was selected using a combination of the white pages and random digit dialling. The proportions of respondents who recalled seeing or hearing about conditions or treatments in the media over the 12 months prior to interview (August 2009–August 2010) and their subsequent health related behaviour. Although most survey participants reported seeking health information from their doctors, around two-thirds of survey participants (551, 68.8%) recalled hearing, seeing or reading about one or more medical conditions (total = 1097 instances) in the mainstream media over the past 12 months. Almost 40% of respondents (307, 38.4%) stated that they had looked for more information about a condition as a result of hearing about it in the media, and most used the internet (269, 87.4%). More than a quarter of respondents (215, 26.9%) indicated that they had asked their doctor about a condition they had heard about in the media. Around half of those who asked their doctor (109, 50.6%) reported that their inquiry resulted in them receiving treatment, of whom almost half (53, 48.3%) reported being prescribed a medicine. The survey results show that consumers become aware of medicines through traditional media and then to learn more often turn to the internet where quality of information may be poor. (252 words)
- 3 April 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (4) , e34314
Open AccessA Prompt to the Web: The Media and Health Information Seeking Behaviour
The objective was to investigate media influence on consumers' health related behaviours. A cross-sectional survey of randomly selected adults (18+ years) residing in the Hunter Region of New South Wales Australia was conducted. The sample was selected using a combination of the white pages and random digit dialling. The proportions of respondents who recalled seeing or hearing about conditions or treatments in the media over the 12 months prior to interview (August 2009–August 2010) and their subsequent health related behaviour. Although most survey participants reported seeking health information from their doctors, around two-thirds of survey participants (551, 68.8%) recalled hearing, seeing or reading about one or more medical conditions (total = 1097 instances) in the mainstream media over the past 12 months. Almost 40% of respondents (307, 38.4%) stated that they had looked for more information about a condition as a result of hearing about it in the media, and most used the internet (269, 87.4%). More than a quarter of respondents (215, 26.9%) indicated that they had asked their doctor about a condition they had heard about in the media. Around half of those who asked their doctor (109, 50.6%) reported that their inquiry resulted in them receiving treatment, of whom almost half (53, 48.3%) reported being prescribed a medicine. The survey results show that consumers become aware of medicines through traditional media and then to learn more often turn to the internet where quality of information may be poor. (252 words)
- Open Access
- 24 November 2011
- Published by Springer Nature in BMC Public Health
- Vol. 11 (1) , 892
An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?
When a medicine such as rofecoxib (Vioxx) is withdrawn, or a whole class of medicines discredited such as the selective COX-2 inhibitors (COX-2s), follow-up of impacts at consumer level can be difficult and costly. The Australian Longitudinal Study on Women's Health provides a rare opportunity to examine individual consumer medicine use following a major discrediting event, the withdrawal of rofecoxib and issuing of safety warnings on the COX-2 class of medicines. The overall objective of this paper was to examine the impact of this discrediting event on dispensing of the COX-2 class of medicines, by describing medicine switching behaviours of older Australian women using rofecoxib in September 2004; the uptake of other COX-2s; and the characteristics of women who continued using a COX-2.
- 24 November 2011
- Published by Springer Nature in BMC Public Health
- Vol. 11 (1) , 892
Open AccessAn observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?
When a medicine such as rofecoxib (Vioxx) is withdrawn, or a whole class of medicines discredited such as the selective COX-2 inhibitors (COX-2s), follow-up of impacts at consumer level can be difficult and costly. The Australian Longitudinal Study on Women's Health provides a rare opportunity to examine individual consumer medicine use following a major discrediting event, the withdrawal of rofecoxib and issuing of safety warnings on the COX-2 class of medicines. The overall objective of this paper was to examine the impact of this discrediting event on dispensing of the COX-2 class of medicines, by describing medicine switching behaviours of older Australian women using rofecoxib in September 2004; the uptake of other COX-2s; and the characteristics of women who continued using a COX-2.